Testing a new treatment for relapsed glioblastoma

Citadel-123: a Phase I Clinical Trial to Assess the Activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I Inhibitor (123I-ATT001) Directly Administered in Subjects with Relapsed Glioblastoma.

This study is testing a new treatment called 123I-ATT001 for people with relapsed glioblastoma to see if it's safe and how well it works when combined with other therapies.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 67 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Theragnostics Ltd (Industry-sponsored)
• Drugs / interventions: Chemotherapy, Immunotherapy, radiation
• Locations: 2 sites (London and 1 other locations)
• Trial ID: NCT06650605 on ClinicalTrials.gov

What this trial studies

This is a Phase 1 open-label trial evaluating the safety and tolerability of 123I-ATT001 in patients with relapsed glioblastoma. The study consists of two parts: the first part involves a dose escalation to determine the maximum tolerated dose of 123I-ATT001 administered weekly for four weeks, while the second part will assess the efficacy of this treatment in combination with other therapies. Participants will be monitored for side effects and overall health throughout the trial.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 with histologically confirmed recurrent glioblastoma and no suitable standard care options available.

Not a fit: Patients with non-recurrent glioblastoma or those who have already received multiple lines of treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with relapsed glioblastoma who currently have limited treatment choices.

How similar studies have performed: While this approach is novel, similar studies targeting glioblastoma have shown promise in exploring new treatment modalities.

Eligibility criteria

Inclusion Criteria:

1. written informed consent
2. Men and women over 18 years of age.
3. Histologically confirmed recurrent glioblastoma (grade IV) as per WHO criteria 2021 (IDH- wild type only) where the subjects have an Ommaya reservoir in an intralesional cavity of at least 5 mL volume.
4. Documented recurrent disease (radiological, based on RANO v.1.0) within 3 months prior to first study drug administration with no suitable standard of care options available.
5. Eastern Cooperative Oncology Group Performance status of 0 or 1.
6. Adequate organ function
7. Women of childbearing potential must use two forms of reliable contraception before starting 123I-ATT001 treatment, during therapy and for 6 months after receiving the last dose of 123I-ATT001. All male subjects must agree to not donate sperm during the study and for 6 months after the last dose of study drug.
8. Be able to understand and comply with the requirements of the study, as judged by the Investigator.

Exclusion Criteria:

1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
2. Diagnosis of immunodeficiency or receiving systemic steroid therapy of up to 4 mg/ day dexamethasone or equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
3. Prior anticancer treatments within the following time periods:

   1. Chemotherapy within 4 weeks of enrolment or 5 half-lives, whichever is shorter.
   2. Targeted small molecule therapy within 4 weeks of enrolment or 5 half-lives, whichever is shorter.
   3. Immunotherapy (including monoclonal antibody therapy) or radiation therapy within 4 weeks prior to study day 1.
4. Unresolved NCI-CTCAE grade 2 or higher toxicity (except stable neurological toxicities/deficits related to disease process, alopecia).
5. Patients with a known allergy to Olaparib or Iodine.
6. Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
7. Any condition that precludes the proper performance of SPECT and/or MRI scan
8. Any clinically significant abnormalities in resting ECG at the time of screening including prolonged QTcF (\>450 ms for males; \>470 ms for females) and cardiac arrhythmias, as judged by the Investigator or designee.
9. Unstable systemic disease (including but not limited to active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
10. Psychiatric, substance misuse or functional disorders that prevent subjects from providing informed consent, following protocol instructions or cooperating with the requirements of the study.
11. Active infection requiring systemic therapy.
12. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 3 months after the last dose of study treatment.
13. Subject that has a condition or is in a situation, which in the Investigators opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
14. History of non- infectious pneumonitis within the last 3 years.

Where this trial is running

London and 1 other locations

• University College London Hosptial — London, United Kingdom (Recruiting)
• University Hospital Southampton — Southampton, United Kingdom (Not_yet_recruiting)

Study contacts

• Principal investigator: Paul Mulholland — University College London Hospital
• Study coordinator: Citadel-123 Admin

Conditions Glioma Glioblastoma Multiforme